What is Ambiq Micro's gross profit margin?

What were the key takeaways from Ambiq Micro's earnings call?

What is Ambiq Micro's latest dividend and current dividend yield?

What factors drove the changes in Ambiq Micro's revenue and profit?

Did Ambiq Micro beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Ambiq Micro next quarter?

What were the key takeaways from Ambiq Micro’s earnings call?

What guidance did Ambiq Micro's management provide for the next earnings period?

- **Revenue Growth Acceleration**: Q4 2025 net sales of $20.7M, up 2% YoY, with full-year gross profit up 32.1%. 2026 expected to surpass $100M driven by Apollo5 adoption and new customers.
- **AI-Driven Innovation**: 80%+ of units running AI in 2025; Atomiq delivers 4x power efficiency with 300mV operation, targeting advanced wearables and industrial AI.
- **Margin Expansion**: Non-GAAP gross margin expanded to 45.5% in Q4 2025, with 2026 focus on Apollo5 yield improvements and Atomiq development.
- **Strategic Investments**: $30M OpEx increase in 2026 for R&D, contract engineering, and IP; $76.8M follow-on offering strengthens cash position.
- **Market Diversification**: 25% of design funnel in industrial/medical, with wins in predictive maintenance, smart buildings, and health monitoring.

**【CEO Summary Section】**
- **Q4 2025 Performance**: Net sales of $20.7 million, exceeding guidance, driven by strong end-user demand and Apollo5 adoption. Full-year gross profit increased 32.1% to a record high.
- **2025 Milestones**: 80%+ of units shipped ran AI algorithms; launched Apollo510 series and Helia AI software ecosystem; completed IPO with $140.3M in cash.
- **2026 Outlook**: Expect >$100M revenue, fueled by new customer ramps, Apollo5 upgrades, and Atomiq product development. Targeting high-growth markets like advanced wearables, smart cameras, and industrial AI.
- **Product Innovation**: Announced Atomiq (300mV operation, 4x power efficiency vs. standard 12nm), Apollo340 (low-cost, scalable platform), and Helia AI runtime for real-time health analysis.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: Non-GAAP gross margin expanded to 45.5% (vs. 25.8% in Q4 2024), driven by strategic repositioning away from Mainland China. Non-GAAP net loss of $5.9M improved 24% YoY.
- **2026 Guidance**: 
  - Q1 2026: Net sales $21-22M, gross margin 44-45%, OpEx $18-18.5M
  - Full year: ~$30M OpEx increase (R&D, contract engineering, IP purchases), targeting Apollo5 yield improvements and Atomiq development.
  - Cash position strengthened by $76.8M follow-on offering, enabling growth investments.
- **Key Trends**: Gross profit growth outpacing sales (32.1% vs. 4.7% in 2025); operating expenses accelerating to support product roadmaps.

**【Q&A Key Highlights】**
- **Revenue Growth**: CEO expects 2026 revenue to surpass $100M, with Q1-Q3 growth driven by new customer ramps and Apollo5 adoption. Seasonality may shift from traditional Q4 peak due to diversifying end markets.
- **Power Efficiency**: SPOT's 300mV operation provides 4x power advantage vs. standard 12nm (700mV). Atomiq enables next-gen wearables, smart cameras, and industrial AI.
- **Market Diversification**: 25% of design funnel now in industrial/medical, with wins in predictive maintenance, smart buildings, and health monitoring devices.
- **OpEx Volatility**: 2026 OpEx increase (~$30M) will be weighted towards Q2-Q3 for IP purchases, contract engineering, and tape-out activities.
- **Gross Margin Risks**: Industry-wide component cost increases could pressure margins, but yield improvements and product mix will offset部分影响。
- **New Customer Ramp**: Major global customer entering mass production in Q1 2026, with significant growth expected in 2027.


Ambiq Micro, Inc.(AMBQ)-20260305-2025 Q4 Earnings call transcript

- **Revenue Beat and Margin Expansion**: Q3 net sales $18.2M, gross margin 44.8% (10.8pts YoY). Q4 guidance $18.5M-$19.5M (+38% YoY) driven by Apollo 5 adoption and new customers.
- **New Product Momentum**: Apollo 510 Lite, Helio AI Runtime, and Atomic platform (2028 launch) driving edge AI innovation in wearables, industrial, and AR.
- **Strategic Shift Success**: China sales reduced to 6.7% of revenue, enabling higher-margin non-China business growth.
- **2026 Outlook**: Apollo 5 and derivative products to fuel growth, with Atomic platform contributing from 2028. Gross margin expansion and OpEx investments for long-term value.

**【CEO Summary Section】**
- **Revenue Growth and Margins**: Exceeded Q3 net sales expectations with $18.2M, down 10.4% YoY due to strategic shift away from China. Gross margin expanded to 44.8%, up 10.8pts YoY. Q4 guidance: $18.5M-$19.5M (vs. consensus $14.2M), driven by Apollo 5 adoption and new customers.
- **Product Launches**: Launched Apollo 510 Lite SOC, Helio AI Runtime, and advanced analytics tools. New customer wins in healthcare, industrial, and smart buildings. Major customer plans 2027 Apollo 5-based platform launch.
- **Strategic Priorities**: 
  1. Expand into high-growth edge AI markets (healthcare, industrial, smart homes)
  2. Innovate with Atomic platform (NPU, 12nm, built-in DRAM/GPU) targeting 2028
  3. Develop Spot into licensable IP within 3-5 years
- **Market Trends**: Convergence of consumer electronics and medical-grade products via HSA/FSA funding for wearables. Edge AI demand growing in wearables, industrial, and smart devices.

**【CFO Financial Commentary】**
- **Q3 Financials**: 
  - Non-GAAP gross profit: $8.1M (16.8% YoY growth)
  - Non-GAAP gross margin: 44.8% (207bps sequential expansion)
  - China sales: 6.7% of net sales (50% YoY decline)
  - Sequential net sales growth: 1.6% to $18.2M
- **Expense Breakdown**: 
  - R&D: $6.9M (7.3% YoY decline)
  - SG&A: $6.2M (12.3% YoY increase)
  - Other income: $1M (40% YoY growth)
- **Q4 Guidance**: 
  - Revenue: $18.5M-$19.5M
  - Non-GAAP loss per share: $0.44-$0.34
  - Includes $1M-$1.5M OpEx increase from IP licensing reclassification
- **2026 Outlook**: 
  - Apollo 5 and derivative products to drive growth
  - Atomic platform expected to contribute meaningfully in 2028
  - Gross margin expansion and revenue growth trajectory

**【Q&A Highlights】**
- **Revenue Drivers**: Strong demand from existing customers (Apollo 5 adoption) and new customers in healthcare, industrial, and smart devices. Apollo 5 ASPs higher than legacy products.
- **Gross Margin Expectations**: Mid-40% range for 2025, with potential for slight improvement in Q4. Sequential gross profit growth due to product mix.
- **Atomic Platform**: Deep in development with customer collaboration. No specific timeline, but engineering team focused on energy efficiency and use case prototyping.
- **2026 Pipeline**: Cautiously optimistic with growing pipeline for Apollo 5, 330 Plus, and 510 Lite. Edge AI use cases expanding into AR glasses, predictive maintenance, and smart grids.
- **Seasonality**: Core wearable business has seasonality, but new customer wins and product adoption offsetting seasonal trends.


Ambiq Micro Inc (AMBQ) Q3 2025 Earnings Call Transcript

- **Revenue diversification success**: China sales reduced to 11.5% of Q2 2025 revenue (from 66% in 2023), driving gross margin to 42.7%.
- **New customer wins**: Whoop's fitness tracker uses Apollo510B for 10x battery efficiency improvement; AR/medical pipeline at 17%+.
- **Strategic growth**: $97.2M IPO proceeds fuel expansion into medical, AR, and SPOT IP licensing for data centers.
- **Q3 guidance**: Revenue $17.5-18M, with stable gross margin and cautious optimism on macro trends.
- **Innovation momentum**: Atomic family in development for high-performance edge AI; SPOT IP for automotive and data centers in 3-5 years.

**【CEO Summary Section】**
- Ambiq's mission is to enable AI at the edge with ultra-low power semiconductors. The SPOT platform reduces system power consumption, enabling AI on battery-powered devices.
- Revenue diversification: China sales dropped from 66% in 2023 to 11.5% in Q2 2025, reflecting strategic focus on higher-value global markets.
- Key wins include Whoop's fitness tracker (Apollo510B) and expansion into AR/VR, medical monitoring, and industrial IoT.
- Strategic initiatives: 1) Market expansion (wearables, medical, AR), 2) New product lines (Atomic family for high-performance edge AI), 3) SPOT IP licensing for data centers and automotive over 3-5 years.

**【CFO Financial Commentary】**
- Q2 2025 revenue: $17.9 million (sequential +13%, YoY -11%), driven by product mix shift away from China.
- Non-GAAP gross margin: 42.7% (vs. 47.1% Q1, 32.9% Q2 2024), reflecting higher-margin sales outside China.
- Operating expenses: $13.8 million (stable vs. Q1), with R&D investment for product pipeline.
- IPO proceeds: $97.2 million, supporting growth initiatives.
- Q3 2025 guidance: Revenue $17.5-18 million, non-GAAP loss per share $0.35-$0.28.

**【Q&A Key Highlights】**
- **Edge AI adoption**: >50% of current sales involve on-device AI processing; medical/industrial funnel at 17%+.
- **Tariff impact**: Q2 saw pull-ahead demand; Q3 outlook cautious but optimistic due to reduced tariff uncertainty.
- **Order lead times**: 16-week average; Q3 order book suggests healthy second-half trends.
- **Atomic progress**: Early adopters engaged; targeting vision-based edge AI applications.
- **SPOT IP licensing**: Data center and automotive customers expressing interest in 12nm SPOT platform development.

Actual	-0.43	-0.22	-0.32
Forecast	-0.4415	-0.3296	-0.3834
Surprise	+2.60%	+33.25%	+16.54%

Actual	17.87M	18.16M	20.74M
Forecast	17.75M	17.76M	19.00M
Surprise	+0.68%	+2.29%	+9.19%

AMBQ

AMBQ fundamentals

AMBQ Q4 2025 Earnings

Earnings Call

You can ask Aime

AMBQ

AMBQ fundamentals

AMBQ Q4 2025 Earnings

Earnings Call

AMBQ Earnings Call Summary for Q4/20258:30 AM on Mar 5, 2026

AMBQ Earnings Call Summary for Q3/20255:00 PM on Nov 6, 2025

AMBQ Earnings Call Summary for Q2/20254:30 PM on Sep 4, 2025

You can ask Aime